Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Jayaprakasam Bolleddula, Kevin DeMent, James P. Driscoll, Philip Worboys, Patrick J. Brassil & David L. Bourdet. (2014) Biotransformation and bioactivation reactions of alicyclic amines in drug molecules. Drug Metabolism Reviews 46:3, pages 379-419.
Read now
Read now
Umberto Leone Roberti Maggiore, Stefano Salvatore, Franco Alessandri, Valentino Remorgida, Massimo Origoni, Massimo Candiani, Pier Luigi Venturini & Simone Ferrero. (2012) Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. Expert Opinion on Drug Metabolism & Toxicology 8:11, pages 1387-1408.
Read now
Read now
Norman, Zinner. (2007) Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder. Expert Opinion on Pharmacotherapy 8:4, pages 511-523.
Read now
Read now
Arun Sahai, Mohammed Shamim Khan, Manit Arya, Jason John, Rajinder Singh & Hitendra RH Patel. (2006) The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy. Expert Opinion on Pharmacotherapy 7:5, pages 509-527.
Read now
Read now
Swati Jha & Matthew Parsons. (2006) Treatment of overactive bladder in the aging population: focus on darifenacin. Clinical Interventions in Aging 1:4, pages 309-316.
Read now
Read now
Christopher R Chapple. (2004) Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder. Expert Opinion on Investigational Drugs 13:11, pages 1493-1500.
Read now
Read now
Articles from other publishers (24)
Shanna C. Trenaman, Susan K. Bowles, Melissa K. Andrew & Kerry Goralski. (2021) The role of sex, age and genetic polymorphisms of CYP enzymes on the pharmacokinetics of anticholinergic drugs. Pharmacology Research & Perspectives 9:3.
Crossref
Crossref
Kuanglei Wang, Hongxi Zhu, Hongqian Zhao, Kun Zhang & Yongshou Tian. (2020) Application of carbamyl in structural optimization. Bioorganic Chemistry 98, pages 103757.
Crossref
Crossref
Oliver Fischer, Josefa Hofmann, Hannelore Rampp, Jonas Kaindl, Gerald Pratsch, Amelie Bartuschat, R. Verena Taudte, Martin F. Fromm, Harald Hübner, Peter Gmeiner & Markus R. Heinrich. (2020) Regiospecific Introduction of Halogens on the 2-Aminobiphenyl Subunit Leading to Highly Potent and Selective M3 Muscarinic Acetylcholine Receptor Antagonists and Weak Inverse Agonists. Journal of Medicinal Chemistry 63:8, pages 4349-4369.
Crossref
Crossref
Hongtao LiuJosefa HofmannInbar FishBenjamin SchaakeKatrin EitelAmelie BartuschatJonas KaindlHannelore RamppAshutosh BanerjeeHarald HübnerMary J. ClarkSandra G. VincentJohn T. FisherMarkus R. HeinrichKunio HirataXiangyu LiuRoger K. SunaharaBrian K. ShoichetBrian K. Kobilka & Peter Gmeiner. (2018) Structure-guided development of selective M3 muscarinic acetylcholine receptor antagonists. Proceedings of the National Academy of Sciences 115:47, pages 12046-12050.
Crossref
Crossref
M.M. Hefnawy, A.M. Alanazi, M.A. Abounassif, M.S. Mohammed, Sabry M. Attia & G.A.E. Mostafa. (2014) Validated liquid chromatographic–fluorescence method for the quantitation of darifenacin in mice plasma and its application to a pharmacokinetic study. Talanta 121, pages 37-42.
Crossref
Crossref
Jing Dai. 2014. Handbook of Metabolic Pathways of Xenobiotics. Handbook of Metabolic Pathways of Xenobiotics
1
3
.
Thejomoorthy Karavadi & B. R. Challa. (2012) Method Development and Validation of Darifenacin in Rat Plasma by Liquid Chromatography-Tandem Mass Spectrometry: Application to a Pharmacokinetic Study. ISRN Spectroscopy 2012, pages 1-9.
Crossref
Crossref
Donald J. AbrahamJulian Blagg. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
301
334
.
Karl-Erik Andersson, Claudius Fullhase & Roberto Soler. (2008) Urothelial effects of oral agents for overactive bladder. Current Urology Reports 9:6, pages 459-464.
Crossref
Crossref
Bertil FM Blok & Jacques Corcos. (2007) Darifenacin for the treatment of overactive bladder. Aging Health 3:2, pages 143-147.
Crossref
Crossref
Richard Jewell. 2007. xPharm: The Comprehensive Pharmacology Reference. xPharm: The Comprehensive Pharmacology Reference
1
5
.
CR Chapple. (2006) The contemporary pharmacological management of overactive bladder. BJOG: An International Journal of Obstetrics & Gynaecology 113, pages 19-28.
Crossref
Crossref
Martin C. Michel & Sharath S. Hegde. (2006) Treatment of the overactive bladder syndrome with muscarinic receptor antagonists - a matter of metabolites?. Naunyn-Schmiedeberg's Archives of Pharmacology 374:2, pages 79-85.
Crossref
Crossref
Andrej Skerjanec. (2006) The Clinical Pharmacokinetics of Darifenacin. Clinical Pharmacokinetics 45:4, pages 325-350.
Crossref
Crossref
Jean-Philippe Starck, Patrice Talaga, Luc Quéré, Philippe Collart, Bernard Christophe, Patrick Lo Brutto, Sophie Jadot, Dinesh Chimmanamada, Matteo Zanda, Alain Wagner, Charles Mioskowski, Roy Massingham & Michel Guyaux. (2006) Potent anti-muscarinic activity in a novel series of quinuclidine derivatives. Bioorganic & Medicinal Chemistry Letters 16:2, pages 373-377.
Crossref
Crossref
François Haab. (2016) Darifenacin for the Treatment of Overactive Bladder. Women's Health 1:3, pages 331-343.
Crossref
Crossref
M. Parsons, D. Robinson & L. Cardozo. (2005) Darifenacin in the treatment of overactive bladder. International Journal of Clinical Practice 59:7, pages 831-838.
Crossref
Crossref
David R. P. Guay. (2005) Darifenacin: Another Antimuscarinic for Overactive Bladder. The Consultant Pharmacist 20:5, pages 424-431.
Crossref
Crossref
Thomas Kerbusch, Peter A. Milligan & Mats O. Karlsson. (2003) Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data. British Journal of Clinical Pharmacology 57:2, pages 170-180.
Crossref
Crossref
Thomas Kerbusch, Ulrika Wählby, Peter A. Milligan & Mats O. Karlsson. (2003)
Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism,
CYP2D6
genotype and formulation-dependent bioavailability
. British Journal of Clinical Pharmacology 56:6, pages 639-652.
Crossref
Crossref
Toshihiro Wajima, Kazuya Fukumura, Yoshitaka Yano & Takayoshi Oguma. (2003) Prediction of Human Pharmacokinetics from Animal Data and Molecular Structural Parameters using Multivariate Regression Analysis: Oral Clearance. Journal of Pharmaceutical Sciences 92:12, pages 2427-2440.
Crossref
Crossref
Koichi Miyamae, Masaki Yoshida, Shigetaka Murakami, Hitoshi Iwashita, Masayuki Ohtani, Koichi Masunaga & Shoichi Ueda. (2003) Pharmacological Effects of Darifenacin on Human Isolated Urinary Bladder. Pharmacology 69:4, pages 205-211.
Crossref
Crossref
Bernd Disse. 2001. Muscarinic Receptors in Airways Diseases. Muscarinic Receptors in Airways Diseases
221
258
.
R. F. Venn & R. J. Goody. (1999) Synthesis and properties of molecular imprints of darifenacin: The potential of molecular imprinting for bioanalysis. Chromatographia 50:7-8, pages 407-414.
Crossref
Crossref